David McMullin, Chief Commerical Officer at Aldeyra Therapeutics, Inc. (ALDX), bought 4,329 shares at $4.68 ($20K) on 2019-09-05, disclosed to the SEC on 2019-09-09.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.